secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lipocine Inc. (LPCN)
CIK:        0001535955
Form:       8-K
Filed at:   2024-03-07T23:59:59+00:00
Accession:  0001493152-24-009128
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lipocine reports FY2023 net loss $16.4M; signs TLANDO license deal with Verity Pharma for $11M upfront
--------------------------------------------------------------------------------

- Net loss $16.4M ($3.14 diluted EPS) in 2023 vs $10.8M loss in 2022; revenue reversal of $2.9M from Antares termination.
- Entered exclusive license with Verity Pharma for TLANDO in U.S./Canada; received $7.5M of $11M upfront, up to $259M milestones, 12-18% royalties.
- Cash $22.0M at 2023 year-end; subsequent $7.5M from Verity brings pro-forma cash to ~$29.5M.
- LPCN 1154 oral brexanolone: positive PK bridge study; pivotal study starts Q1'24, NDA filing expected Q4'24.
- LPCN 1148 Phase 2 POC met primary endpoint for decompensated cirrhosis; fewer HE events, symptom improvement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1535955/000149315224009128/0001493152-24-009128-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1535955/000149315224009128/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-009128

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer